What is Investigational New Drug ?
2493 reads · Last updated: December 5, 2024
An Investigational New Drug (IND) is a drug that has not yet received market approval and is being evaluated for safety and efficacy in humans. INDs are typically developed by pharmaceutical companies or research institutions and must receive approval from relevant regulatory authorities (such as the U.S. Food and Drug Administration, FDA) before proceeding with clinical trials.Key characteristics include:Development Stage: INDs are in the preclinical or clinical trial stages of drug development and have not yet received market approval.Clinical Trials: INDs are used to conduct human clinical trials to assess their therapeutic effects, safety, and dosage range.Regulatory Approval: An IND application must be submitted and approved by regulatory authorities before clinical trials can begin.Data Collection: Data collected during clinical trials are used to support future New Drug Application (NDA) submissions.Example of Investigational New Drug application:Suppose a pharmaceutical company develops a new anti-cancer drug that has shown promising results in animal studies. The company submits an IND application to the FDA, including the drug's chemical composition, manufacturing process, animal study data, and planned clinical trial protocol. After FDA review and approval, the company begins human clinical trials to evaluate the drug's safety and efficacy.
Definition
An Investigational New Drug (IND) refers to a drug that has not yet received market approval and is used to evaluate its safety and efficacy in humans. INDs are typically developed by pharmaceutical companies or research institutions and must receive approval from relevant regulatory bodies (such as the U.S. Food and Drug Administration, FDA) before clinical trials can begin.
Origin
The concept of Investigational New Drugs originated from the need for rigorous drug development processes, particularly in the mid-20th century, as drug development became more complex. The legal framework for INDs was formally established by the FDA with the Drug Amendments of 1962.
Categories and Features
INDs are primarily categorized into the following stages:
1. Preclinical Stage: At this stage, the drug is tested in laboratories and on animals to assess its basic safety and biological activity.
2. Clinical Trial Stage: This includes Phase I, II, and III trials, which evaluate the drug's safety, efficacy, and optimal dosage.
Features include:
Development Stage: INDs are in the preclinical or clinical trial stages of drug development and have not yet received market approval.
Clinical Trials: INDs are used in human clinical trials to assess therapeutic effects, safety, and dosage range.
Regulatory Approval: An IND application must be submitted and approved by regulatory bodies before clinical trials can commence.
Data Collection: Data collected during clinical trials support future New Drug Applications (NDA).
Case Studies
Case Study 1: A pharmaceutical company developed a new cancer drug that showed promising results in animal studies. The company submitted an IND application to the FDA, including the drug's chemical composition, manufacturing process, animal study data, and planned clinical trial protocol. After FDA approval, the company began human clinical trials to evaluate the drug's safety and efficacy.
Case Study 2: Another biotech company developed a new drug for a rare genetic disorder. After initial laboratory research, the company submitted an IND application and, upon approval, began Phase I clinical trials in a small patient group to determine a safe dosage.
Common Issues
Common issues include:
1. What are the reasons for an IND application being rejected? Typically due to insufficient data, unreasonable trial design, or safety concerns.
2. What is the difference between IND and NDA? IND is for the clinical trial phase application, while NDA is for drug marketing approval.
